NVision Imaging Technologies develops the POLARIS hyperpolarization device based on parahydrogen-induced polarization, which amplifies MRI signals of natural metabolites such as 13C-pyruvate by more than 10,000 times for metabolic imaging on existing MRI scanners. The device enables high-throughput dose production in 3 minutes per dose with room-temperature processing, a small footprint under 1 m², and no need for infrastructure changes. It targets oncology for assessing early treatment response and tumor viability, with applications in cardiology, hepatology, nephrology, neurology, and rheumatology; deployments include Technical University of Munich and University of Cambridge. The company secured a Series A round exceeding $30M in June 2023 led by investors including Pathena, with total funding over $87M including multiple grants up to 2025. Founded in 2015 by Sella Brosh (CEO, M.D.), Ilai Schwartz (Co-Founder and CTO), Prof. Martin Plenio (Co-Founder), Prof. Fedor Jelezko (Co-Founder), and Prof. Alex Retzker (Co-Founder). Headquartered in Ulm, Germany.